Pharvaris N.V.
PHVS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001830487
In the last 90 days, Pharvaris N.V. insiders filed 0 open-market purchases and 20 sales; 125 institutions reported holding it in 13F filings for Q2 2026, worth $2.23B in total; Viking Global Investors is the only superinvestor holding it.
13F holders, Q4 2025
Institutional positions in Pharvaris N.V. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 106
- +25 vs. Q3 2025
- Shares held
- 59.0M
- +1.21M (+2.1%) vs. Q3 2025
- Total value
- $1.64B
- +$195.2M (+13.5%) vs. Q3 2025
- New holders
- 31
- 42 more added
- Sold out
- 6
- 15 more reduced
2 institutions that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PHVS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 125 | $2.23B |
| Q1 2026 | 110 | $1.67B |
| Q4 2025 | 106 | $1.64B |
| Q3 2025 | 83 | $1.44B |
| Q2 2025 | 60 | $792.7M |
| Q1 2025 | 52 | $705.5M |
| Q4 2024 | 54 | $855.8M |
| Q3 2024 | 51 | $834.2M |
| Q2 2024 | 36 | $808.6M |
| Q1 2024 | 35 | $980.5M |
| Q4 2023 | 36 | $1.14B |
| Q3 2023 | 21 | $606.6M |
| Q2 2023 | 21 | $441.6M |
| Q1 2023 | 21 | $173.9M |
| Q4 2022 | 25 | $239.6M |
| Q3 2022 | 21 | $173.6M |
| Q2 2022 | 20 | $494.0M |
| Q1 2022 | 22 | $397.1M |
| Q4 2021 | 22 | $321.1M |
| Q3 2021 | 25 | $380.3M |
| Q2 2021 | 28 | $406.3M |
| Q1 2021 | 33 | $616.5M |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Pharvaris N.V.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| EQT Fund Management S.a r.l. | 3,424,609 | $95.0M | 8.55% | 00.0% | Unchanged |
| Viking Global Investors LPSuperinvestorViking Global Investors | 3,653,310 | $101.4M | 0.27% | 00.0% | Unchanged |
| venBio Partners LLC | 4,639,304 | $128.7M | 59.53% | 00.0% | Unchanged |
| Foresite Capital Management IV, LLC | 4,778,581 | $132.6M | 57.73% | 00.0% | Unchanged |
| FMR LLC | 6,399,158 | $177.6M | 0.01% | 00.0% | Unchanged |
| General Atlantic LLC | 8,031,252 | $222.9M | 7.76% | 00.0% | Unchanged |
| Paradigm Biocapital Advisors LP | 0 | $0 | 0.00% | −1,835,494−100.0% | Sold out |
| VR Adviser, LLC | 0 | $0 | 0.00% | −674,599−100.0% | Sold out |
| Integral Health Asset Management, LLC | 0 | $0 | 0.00% | −200,000−100.0% | Sold out |
| Silverarc Capital Management, LLC | 0 | $0 | 0.00% | −183,903−100.0% | Sold out |
| Woodline Partners LP | 0 | $0 | 0.00% | −100,000−100.0% | Sold out |
| Quarry LP | 0 | $0 | 0.00% | −442−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | – | – | – | – | Not filed |
| Point72 Asia (Singapore) Pte. Ltd. | – | – | – | – | Not filed |